

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai HeartCare Medical Technology  
Corporation Limited**

**上海心瑋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6609)**

**PROPOSED ABOLISHMENT  
OF THE SUPERVISORY COMMITTEE; AND  
PROPOSED AMENDMENTS TO  
ARTICLES OF ASSOCIATION**

This announcement is made by Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”) pursuant to Rules 13.51(1) and 13.51(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces that the Company intends to put forward proposals to the shareholders of the Company (the “**Shareholders**”) to abolish the supervisory committee of the Company (the “**Supervisory Committee**”) and amend the existing articles of association of the Company (the “**Articles**”).

**PROPOSED ABOLISHMENT OF THE SUPERVISORY COMMITTEE**

Pursuant to the amendments to the Company Law of the People's Republic of China 《(中華人民共和國公司法)》 effective on July 1, 2024 (the “**New Company Law**”), a joint stock limited company may, in accordance with its articles of association, instead of establishing a supervisory committee, establish an audit committee which comprises Directors and discharges the duties of the supervisory committee as prescribed under the New Company Law.

On December 12, 2025, in light of the New Company Law, the Board resolved and proposed to abolish the Supervisory Committee (the “**Proposed Abolishment**”), following which the duties of the Supervisory Committee will be discharged by the audit committee of the Board (the “**Audit Committee**”).

Pursuant to the Articles and the relevant laws and regulations in the PRC, the Proposed Abolishment is subject to the approval of the Shareholders by way of a special resolution at a general meeting. A special resolution to consider and approve the Proposed Abolishment will be proposed at an extraordinary general meeting of the Company (the “**EGM**”) to be held in due course.

Each of the supervisors of the Company (each a “**Supervisor**”) will resign as a Supervisor conditional upon the approval of the Proposed Abolishment at the EGM and with effect from the date of the EGM. Each of the Supervisors has confirmed that he has no disagreement with the Board or the Supervisory Committee, and there is no matter relating to his proposed resignation that needs to be brought to the attention of the Shareholders or the Stock Exchange. Before that, the Supervisory Committee will continue to exercise the functions and powers as prescribed by the New Company Law and other laws and regulations, as well as the Articles.

## **PROPOSED AMENDMENTS TO ARTICLES OF ASSOCIATION**

In light of the New Company Law and the Proposed Abolishment, as well as the consultation conclusions on “Proposals to Further Expand the Paperless Listing Regime and Other Rule Amendments” published by the Stock Exchange on January 24, 2025, and to further improve the corporate governance of the Company, the Board resolved and proposed to amend the Articles in accordance with the requirements of the New Company Law and the Listing Rules, and make adjustments to certain provisions in the Articles after taking into consideration, among others, the operational and management needs of the Company (collectively, the “**Proposed Amendments**”).

Pursuant to the Articles and the relevant laws and regulations in the PRC, the Proposed Amendments are subject to the approval of the Shareholders by way of a special resolution at a general meeting. A special resolution to consider and approve the Proposed Amendments will be proposed at the EGM in due course.

## **GENERAL**

A circular containing, among others, the details of the Proposed Abolishment and the Proposed Amendments, together with a notice of the EGM, will be sent to the Shareholders in due course in accordance with the Listing Rules.

By Order of the Board  
**Shanghai HeartCare Medical Technology Corporation Limited**  
**WANG Guohui**  
*Chairman of the Board*

Shanghai, December 12, 2025

*As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Ding Kui, Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.*